



EVA360™

Supporting women through life's transitions

www.fagron.com

 **Fagron**
personalizing
medicine

EVA360™

EVA360™ is a patented *Asparagus racemosus* root ingredient produced through a proprietary extraction process to deliver a differentiated phytochemical profile.

Standardized to ≥6% total shatavarins, EVA360™ is characterized by the presence of LI58129, a steroidal saponin associated with ~60% of the activity observed in an *in vitro* estrogen receptor activation*, offering a scientifically defined botanical option for women's well-being supplement applications.

Key Features



Patented
ingredient



Clinically studied
at 200 mg/day



Formulation
flexibility



Women-focused
positioning



Differentiated
profile

The Science behind EVA360™

Clinical Evidence

EVA360™ was clinically evaluated at 200 mg/day in perimenopausal women, with favorable results in validated measures of menopausal well-being and self-perceived skin and hair quality. It was also evaluated in women with polycystic ovary syndrome (PCOS), with favorable findings in selected ovarian, androgen-related, and metabolic parameters.^{1,2}

Biomarker profile:

Secondary findings showed lower follicle-stimulating hormone (FSH) and luteinizing hormone (LH), with higher anti-Müllerian hormone (AMH) and follicle count, aligning with a favorable hormonal and ovarian profile during transition.¹

Broader shatavari clinical context:

Clinical studies using standardized shatavari root extracts have reported favorable outcomes for women's sexual wellness.³



In vitro and preclinical support:

Studies with *Asparagus racemosus* support oxidative balance, steroidogenic activity, and estrogen-responsive pathways.^{4,5,6}

Safety and Quality



Plant-based and
vegan/vegetarian
suitable.



EVA360™ was well
tolerated in clinical
evaluation.



Quality standards
supporting batch-to-batch
consistent quality.



Ideal for daily
supplementation in
women's health formulations.

* Based on supplier-provided technical data from an *in vitro* estrogen receptor activation assay. Published peer-reviewed data specifically confirming this finding were not available at the time of preparation of this material.



How to use EVA360™



Dose
200 mg/day.



Format
Capsules, sachets, gummies, chocolate troches, or tablets, selected according to patient preference and adherence.

For women seeking well-being and quality of life support during hormonally dynamic life stages.

Compounding

EVA360™ is suitable for multiple oral formats, alone or in combination with other nutraceutical ingredients. Excipient compatibility and stability should be assessed during formulation development. Store at or below 25°C, tightly closed and protected from heat, moisture, light, and air to help preserve product quality.

Fagron Academy

Fagron Formulary

the biggest formula database globally, with continuously updated, searchable formulas (including EVA360™), with preparation methods and practical guidance for prescribers and pharmacists.

Video Platform

A multilingual online educational platform that bridges prescribing and compounding in personalized medicine.

- ¹Yadav, P., Yadav, S., Vedururu, S. S., & Kumari, G. (2025). A standardized *Asparagus racemosus* root extract improves hormonal balance and menstrual health and reduces vasomotor symptoms in perimenopausal women: a randomized, Double-Blind, Placebo-Controlled study. *Journal of the American Nutrition Association*, 44(8), 754–764. <https://doi.org/10.1080/27697061.2025.2510474>
- ²Kondamudi, S., Sadu, S., Deva, S., Yalamanchi, A., & Yalamanchi, A. (2026). Safety and efficacy of a proprietary *Asparagus racemosus* root extract on ovarian morphology, androgen balance, and insulin resistance in women diagnosed with polycystic ovary syndrome. *Functional Foods in Health and Disease*, 16(2), 132–154. <https://doi.org/10.31989/ffhd.v16i2.1889>
- ³Ademola, J., Mahajan, S., Srivathsan, M., & Langade, D. (2026). Effects of Shatavari (*Asparagus racemosus*) Root Extract on Sexual Wellness in Women: Findings from a Prospective, Randomized, Double-Blind, Three-Arm, Parallel-Group, Placebo-Controlled Study. *International Journal of Women's Health*, Volume 18, 1–21. <https://doi.org/10.2147/ijwh.s561213>
- ⁴Pandey, V., Sharma, A., Tiwari, S., Patel, Y., Chauhan, J. K., Ayesha, S., Sahu, A. N., Gupta, R., Tripathi, A., & Dubey, P. K. (2024). Shatavarin-IV rescues the Di(2-ethylhexyl) phthalate (DEHP)-induced oxidative stress in rat granulosa cells in vitro. *Reproductive Toxicology*, 130, 108737. <https://doi.org/10.1016/j.reprotox.2024.108737>
- ⁵Singh, N., Garg, M., Prajapati, P., Singh, P. K., Chopra, R., Kumari, A., & Mittal, A. (2023b). Adaptogenic property of *Asparagus racemosus*: Future trends and prospects. *Heliyon*, 9(4), e14932. <https://doi.org/10.1016/j.hvy>
- ⁶Lalert, L., Kruevaisayawan, H., Amatyakul, P., Ingkaninan, K., & Khongsombat, O. (2018). Neuroprotective effect of *Asparagus racemosus* root extract via the enhancement of brain-derived neurotrophic factor and estrogen receptor in ovariectomized rats. *Journal of Ethnopharmacology*, 225, 336–341. <https://doi.org/10.1016/j.jep.2018.07.014>



Disclaimer

This document summarizes information from Fagron materials and independent peer-reviewed literature. Some cited studies were not designed, conducted, or controlled by Fagron, and methodology, endpoints, and interpretations may evolve as new research appears. The content is for informational purposes only. It does not constitute medical advice or a guarantee of safety, efficacy, or bioavailability for any specific patient. Clinicians should use their own judgment, consult original sources, and consider individual patient factors. Regulatory status and permissible claims vary by market (for example, food supplement in the EU, dietary

supplement in the United States). Prescribing, labeling, advertising, and on-pack wording must comply with applicable laws and guidance in each country, including LATAM markets. Use of compounded preparations must comply with professional standards and local regulations (for example, USP <795> or local equivalents). Fagron makes no warranties, express or implied, and assumes no liability for outcomes arising from reliance on this document. Responsibility for clinical decisions and compounding practices rests with the prescribing clinician and the compounding pharmacist.

